All In Biotech

Drug Trial Radar · NCT07136389

Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus

An Open-label, Non-comparative Clinical Study of the Safety, Pharmacokinetics, Immunogenicity BCD-256 and Divozilimab in Monotherapy and Combination Therapy With Single and Multiple Intravenous Administration to Subjects With Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

135

Planned (sponsor's estimate)

Start

Mar 27, 2025

Primary completion

Jan 1, 2026

Study completion Nov 1, 2026

Sponsor

Lead sponsor
BiocadIndustry
Sponsor type
Industry
First posted
Aug 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial to investigate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of BCD-256 alone and in combination with anti-CD20 therapy (divozilimab) as second- or later-line therapy in subjects with skin lesions due to mild to moderate systemic lupus erythematosus. The study consists of the first stage (cohorts 1-5) and the second stage (cohorts A - D).

Conditions

  • Systemic Lupus Erthematosus

Interventions

  • BCD-256Drug

    Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously

  • BCD-256Drug

    Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously

  • BCD-256Drug

    Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously

  • DivozilimabDrug

    Ant-CD0 human monoclonal antibody, Concentrate for solution for infusion intravenously

  • BCD-256Drug

    Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with adverse eventsTime frame: 85 days
  2. Proportion of subjects with serious adverse eventsTime frame: 85 days
  3. Proportion of subjects with treatment-related adverse eventsTime frame: 85 days
  4. Proportion of subjects with CTCAE 5.0 grade ≥ 3 adverse eventsTime frame: 85 days
  5. Proportion of cases of early discontinuation of study therapy due to adverse eventsTime frame: 85 days
  6. Proportion of subjects with adverse events of special interestTime frame: 85 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • "Multidisciplinary medical center for adults and children №157"

    Saint Petersburg, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.